(70 days)
I2C is used with a charged particle or photon radiation therapy system for localization of the patient position with respect to the therapy equipment and to provide correction feedback to the radiation therapy device.
For clinical use, l2C must be integrated into a radiation therapy system. I2C will interact with components of the radiation therapy center. I2C supports the acquisition of 2D, 2D stereoscopic and 3D images using 2D detectors. I2C will be used by the clinical therapist to verify by imaging that the treatment target position received from the treatment control applicative laver is 'valid', i.e. that it brings the center of the treatment target volume at the isocenter of the therapy equipment with required accuracy. If it is not, InC will propose a correction shift - or correction vector - that will be exported to the radiation therapy system.
Here's a summary of the acceptance criteria and study information for the I2C device:
1. Table of Acceptance Criteria and Reported Device Performance
| Performance / Technological Specification | Acceptance Criteria (Predicate Devices) | Reported Device Performance (I2C) |
|---|---|---|
| Generator operating range (radiographic) | 40-150 kVp | 40-150 kVp |
| Generator operating range (CBCT) | 60-140 kVp (OBI) | 40-125 kVp |
| Flat panel pixel size | 127 µm (Verisuite) / 194 µm (OBI) | 148 µm |
| Flat panel pixel matrix | 3200x3200 pixels (Verisuite) / 3200x2304 pixels (OBI) | > 2880x2880 pixels |
| CBCT scale & distance accuracy | 1% (OBI) | 1% |
| CBCT spatial resolution | 4-7 lp/cm (OBI) | At least 5 lp/cm |
| CBCT low contrast resolution | 15mm@1% (OBI) | 15mm@1% |
| CBCT numbers accuracy | +/- 40 HU (OBI) | +/- 40 HU |
| CBCT Uniformity | +/- 40 HU (OBI) | +/- 40 HU |
| Achievable matching accuracy | < 1 mm (Verisuite) / 1-2 mm (ExacTrac) | < 1 mm |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify a distinct "test set" sample size in the traditional sense. Instead, it describes various verification and validation activities:
- Simulated Clinical Environment: The X-Ray imaging equipment was installed on a test bench with a phantom to represent different configuration setups and simulate gantry rotation.
- Communication Testing: A second test environment was used to verify communication with different third-party software configurations (Elekta Mosaiq, Varian Aria).
- Additional Performance Tests: Conducted on a stand-alone system using:
- Appropriate datasets collected from simulated treatments.
- Radiographs of phantoms acquired in IBA treatment centers.
- Anonymized patient data provided by IBA treatment centers.
- User Evaluation: Intermediate releases were distributed to a group of "a-users" (reference users in proton therapy) to assess usability.
The data provenance for the additional performance tests includes:
- Simulated treatments.
- Phantom data acquired in IBA treatment centers.
- Anonymized patient data (from IBA treatment centers).
The document does not explicitly state the country of origin for the patient data, but "IBA treatment centers" suggests it likely comes from facilities where IBA technology is used. The data appears to be retrospective in nature for these tests, as it mentions "anonymised patient data provided by IBA treatment centers."
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The document does not specify the number or qualifications of experts used to establish ground truth for the test set. The validation primarily relies on performance metrics derived from physical phantoms, simulated scenarios, and anonymized patient data.
4. Adjudication Method for the Test Set
No specific adjudication method (e.g., 2+1, 3+1) is mentioned for the test set. The evaluation seems to be based on direct measurement of performance metrics against predefined technological specifications and comparison to predicate devices, rather than a consensus-based expert review for individual cases.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study is not mentioned. The document focuses on the technical performance of the device itself and its equivalence to predicate devices, not on the improvement of human reader performance with or without AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, standalone performance tests were done. The document states: "Third, additional performance tests were done on a stand-alone system with appropriate datasets collected from simulated treatments and radiographs of phantom acquired in IBA treatment centres, and from anonymised patient data provided by IBA treatment centers."
7. The Type of Ground Truth Used
The ground truth used for these non-clinical tests appears to be primarily:
- Physical measurements/known values from phantoms: For accuracy, resolution, contrast, and uniformity tests.
- Simulated treatment parameters: For evaluating the device's ability to process and generate correction vectors in controlled scenarios.
- Anonymized patient data: Used as input for the standalone system, likely comparing its output (e.g., calculated shifts) against expected or clinically established values, though the exact method of ground truth for patient data isn't detailed.
8. The Sample Size for the Training Set
The document does not specify a separate "training set" or its sample size. The focus is on the verification and validation of the developed system, suggesting that the algorithm's training (if any involving machine learning) was either done prior to these V&V activities or is not detailed in this summary.
9. How the Ground Truth for the Training Set Was Established
As no training set is explicitly mentioned or detailed, the method for establishing its ground truth is not provided in this document.
{0}------------------------------------------------
NOV 2 0 2013
- Page 1 of 8
iba
M-Id 39876 Rev. B Page 2
510(k) Summary 12C
510(k) SUMMARY lon Beam Applications S.A.
06 November 2013
Submitter
lon Beam Applications S.A. Chemin du Cyclotron, 3 B-1348 Louvain-la-Neuve Belgium Contact person : Mr Baelen Michel 32-10-47-58-45 Phone : 32-10-47-58-10 Facsimile: E-mail: Michel Baelen@iba-group.com
Contact and Agent for lon Beam Applications S.A. in the US
Bruce D. Armon Saul, Ewing, Remick & Saul Centre Square West 38th Floor Philadelphia, PA 19102-2186 Phone: (215) 972-7124 Facsimile: (215) 972-1906 E-mail: barmon@saul.com
ಗಿ
{1}------------------------------------------------
Name of the Device
I₂C (IBA Image Guided Therapy Consol) (brand name: adapt Insight)
Classification Name
Medical charged-particle radiation therapy systems. (21 C.F.R. §892.5050)
Predicate Devices
I2C is claimed to be equivalent to the predicate devices listed in table 1 below, based on the fact that they have the same intended use and principles of operation, and are substantially equivalent in terms of performance and technological characteristics.
| Device | Indication for use |
|---|---|
| Verisuite(K080742, Medcom) | The VeriSuite patient position verification system is used forverification and correction of the patient's position during aradiotherapy treatment with external beams or charged particles. It isbased on stereoscopic X-ray images and DRRs calculated from a CTimage series of the treatment region of the patient and informationfrom the treatment planning. |
| ExacTrac 3rd Party(K072046, Brainlab) | The ExacTrac 3rd Party system is intended to be used in conjunctionwith the MHI-TM2000 radiation therapy linear accelerator systemmanufactured by Mitsubishi Heavy Industries, Ltd.ExacTrac 3rd Party uses the images received from the MH1-TM2000linear accelerator for analyzing the current patient position andcalculating - when applicable - a necessary correction shift. Thecorrection shift is then exported to the MHI-TM2000 linearaccelerator.The ExacTrac 3rd Party system uses stereoscopic x-ray or conebeam CT registration and optical tracking of infrared reflectivemarkers in order to localize and correct the patient position beforeand during treatment. |
| OBI(K040192 &K042720, Varian) | The On-Board Imager device is used for verification of correct patientposition in relation to isocenter and verification of the treatment fieldsin relation to anatomical and/or fiducial landmarks |
Table 1: List of the identified predicate devices and their indication for use
Indication for Use of the device
IzC is used with a charged particle or photon radiation therapy system for localization of the patient position with respect to the therapy equipment and to provide correction feedback to the radiation therapy system.
{2}------------------------------------------------
Description of the device
For clinical use, l2C must be integrated into a radiation therapy system. I2C will interact with components of the radiation therapy center.
I2C supports the acquisition of 2D, 2D stereoscopic and 3D images using 2D detectors.
I2C will be used by the clinical therapist to verify by imaging that the treatment target position received from the treatment control applicative laver is 'valid', i.e. that it brings the center of the treatment target volume at the isocenter of the therapy equipment with required accuracy. If it is not, InC will propose a correction shift - or correction vector - that will be exported to the radiation therapy system.
Technological Characteristics of the device
1. Image acquisition
The I2C software supports the acquisition of 2D, 2D stereoscopic and 3D images using 2D detectors.
The 2D and 2D stereoscopic images can be acquired using one or multiple imaqing devices arranqed in various geometrical configurations.
The 3D images are created using a single 2D imaging device which rotates around the volume to be imaged: The 3D images are then reconstructed using the acquired 2D images and the associated spatial information (angle of acquisition).
The image acquisition supports a range of OEM devices1, such as the following X-ray tubes, generators and detectors:
| 2D | 2D/3D | |
|---|---|---|
| X-ray tube | Varian B130H | Varian GS2075 |
| Generator | Sedecal SHF835 | Sedecal SHF845RF |
| Detector | Varian Paxscan 4030E | Thales Pixium RF4343 |
13
1 The conformity of these devices and their proper integration into the I-C system were ensured by the verification and validation activities followed during the development of the system and described in 12C VnV plan - MID 37685.
{3}------------------------------------------------
2. Image registration
Image registration is used to verify, based on the reference and acquired images. that the position of the patient in regard to the equipment matches the treatment plan geometry and eventually compute a correction vector that can be applied to ensure correct patient positioning. It has been designed such that a submillimeter matching accuracy can be reached.
The registration provides a correction vector of up to 6 degrees of freedom that can be sent to third party systems.
2D image registration
The 2D or 2D stereoscopic image registration uses either:
- Intensity based information between the acquired X-ray planar images and the Digital Reconstructed Radiograph (DRR) (generated from the treatment planning reference CT) data or provided by Treatment Planning System - TPS -, ... ), this is done automatically, or
- Markers that have been identified on the acquired X-ray planar images and the DRR generated from the CT data, or
- Manual registration of the images by drag and drop of one image to the other one.
3D image registration
The 3D image reqistration uses either
- Intensity based information between the acquired 3D data set and the a CT data, or
- Manual registration of the images by drag and drop of one image to the other one.
- ・ The registration provides a correction vector of 6 degrees of freedom that can be sent to third party system.
3. Connectivity to third party systems
The device exchanges data with 30 party systems such as an Oncology Information System using either a push or a pull method, or any third party system supporting DICOM standards.
{4}------------------------------------------------
Comparison to the predicate devices
Like the predicate devices in Table 1, 12C is designed to be used with a charged particle or photon radiation therapy system for localization of the patient position with respect to the therapy equipment and to provide correction feedback to the radiation therapy device-
The predicate devices also provide the same or substantially equivalent functions, characteristics, and accessories.
Based on the purpose of the 12C system, its environment of use, its main components and features, the following elements have been used for comparison:
- . Intended use
- Radiation type: clinical relevance, patient safety, known technology .
- . Acquisition geometry
- Detector type .
- Image used as reference for matching .
- o Data compared during matching
- . Type of matching approach
- Communication to 3rd party software .
Table 2: Comparison table of I2C with identified predicate devices
| Characteristics | I₂C | Verisuite(K080742,Medcom) | ExacTrac3rd Party(K072046,Brainlab) | OBI(K040192 &K042720,Varian) |
|---|---|---|---|---|
| Indication for use: | ||||
| • Verification of patientsetup position | ✓ | ✓ | ✓ | ✓ |
| • Used with a chargeparticle radiation therapysystem | ✓ | ✓ | ||
| • Used with a photonradiation therapy system | ✓ | ✓ | ✓ | ✓ |
| Image acquisition: | ||||
| • High accuracy kV X-Rayimaging with digital flatpanel | ✓ | ✓ | ✓ | ✓ |
{5}------------------------------------------------
iba
| Characteristics | I₂C | Verisuite(K080742,Medcom) | ExacTrac3rd Party(K072046,Brainlab) | OBI(K040192 &K042720,Varian) |
|---|---|---|---|---|
| • Stereoscopic acquisition | ✓ | ✓ | ✓ | ✓ |
| • Flexible X-Ray setup:various arrangements ofpanels, generators andtubes | ✓ | ✓ | ||
| Image matching: | ||||
| • Registration usinganatomical landmarks | ✓ | ✓ | ✓ | ✓ |
| • Registration using fiduciallandmarks | ✓ | ✓ | ✓ | ✓ |
| • Registration using CBCTwith planning CT | ✓ | ✓ | ||
| • Registration ofradiographs with DRRgenerated from planningCT | ✓ | ✓ | ✓ | ✓ |
| o 2D/2D (5 DOFregistration) | ✓ | ✓ | ✓ | ✓ |
| o 2D/3D (6 DOFregistration) | ✓ | ✓ | ✓ | - |
| Interface to 3rd party applications: | ||||
| • Transfer of correction shift(correction vector) | ✓ | ✓ | ✓ | - |
| • DICOM exchange ofclinical data | ✓ | ✓ | ✓ | ✓ |
Table 3 provides a comparison of 12C with predicate devices for some of characteristic specification.
Table 3: Indication of performance and technological specification of I-C and its predicate devices
| Performance / technologicalspecification | I2C | Verisuite(K080742,Medcom) | ExacTrac3rd Party(K072046,Brainlab) | OBI(K040192 &K042720,Varian) |
|---|---|---|---|---|
| ---------------------------------------------- | ----- | ----------------------------------- | ------------------------------------------------- | ------------------------------------------ |
16
{6}------------------------------------------------
iba
| Performance / technologicalspecification | I2C | Verisuite(K080742,Medcom) | ExacTrac3rd Party(K072046,Brainlab) | OBI(K040192 &K042720,Varian) |
|---|---|---|---|---|
| Generator operating range(radiographic) | 40-150 kVp | 40-150 kVp | - | 40-150 kVp |
| Generator operating range(CBCT) | 40-125 kVp | N/A | N/A | 60-140 kVp |
| Flat panel pixel size | 148 µm | 127 µm | - | 194 µm |
| Flat panel pixel matrix | > 2880x2880pixels | 3200x3200pixels | - | 3200x2304pixels |
| CBCT scale & distanceaccuracy | 1% | N/A | N/A | 1% |
| CBCT spatial resolution | At least 5lp/cm | N/A | N/A | 4-7 lp/cm |
| CBCT low contrast resolution | 15mm@1% | N/A | N/A | 15mm@1% |
| CBCT numbers accuracy | +/- 40 HU | N/A | N/A | +/- 40 HU |
| CBCT Uniformity | +/- 40 HU | N/A | N/A | +/- 40 HU |
| Achievable matching accuracy | < 1 mm | < 1 mm | 1 - 2 mm | - |
Based on the previous analysis and discussion, we can state that for each of its functionalities reqarding its intended use. I2C always has the same technological characteristics and is as safe and effective as at least one of the identified predicate devices. I2C performs as well or better as the identified predicate devices while not providing or using new functionality or technology.
Nonclinical tests for determination of substantial equivalence
When verifying the effectiveness and safety of the design and its implementation, part of the activities was done in a simulated clinical environment with the actual hardware and 30 party software applications. The X-Ray imaging equipment was installed on a test bench in a vault appropriate for radiologic operation. The qeometry of the system was adapted to represent different configuration setups. The rotation of the gantry was simulated by a rotation of the phantom on a turn table driven by a real gantry controller. A configuration of 30 party software applications was setup in order to test the whole treatment workflow scenarios, including exception cases.
{7}------------------------------------------------
K132897
Page 8 of 8
iba
18
A second test environment was used to verify communication with different 30 party software configurations (Elekta Mosaiq, Varian Aria) installed on their dedicated workstations.
Third, additional performance tests were done on a stand-alone system with appropriate datasets collected from simulated treatments and radiographs of phantom acquired in IBA treatment centres, from test bench data acquired with phantoms, and from anonymised patient data provided by IBA treatment centers.
As a fourth verification and validation strategy axis, a process of evaluation by a group of a-users has been put in place to assess the usability of the software. Throughout the development, intermediate releases are distributed to a group of reference users in proton therapy. A process has been put in place to collect a user evaluation of the system, especially reqarding usability.
For a more elaborate description of the V&V activities, please refer to M-ID 37685 (I2C v1: V&V Plan).
Conclusions
In conclusion, the verification and validation activities insure that the device is as safe, as effective, and performs as well as the legally marketed device identified in Table 1.
{8}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/8/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight, composed of three curved lines.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 20. 2013
lon Beam Applications S.A. % Mr. Bruce D. Armon, Partner Saul Ewing LLP Center Square West 1500 Market Street, 38th Floor PHILADELPHIA PA 19102
Re: K132847 Trade/Device Name: I2C Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: LHN Dated: September 9. 2013 Received: September 23, 2013
Dear Mr. Armon:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you. however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting vour device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA`s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act s requirements, including, but not limited to: registration and listing (2 l CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{9}------------------------------------------------
Page 2-Mr. Armon
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.ida.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Michael O. Husa
for
Janine M. Morris Director, Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{10}------------------------------------------------
Indications for Use
510(k) Number (if known): K132847
Device Name: 12C
Indications For Use:
Indications For Use: 12C is used with a charged particle or photon radiation therapy system for localization of the patient position with respect to the therapy equipment and to provide correction feedback to the radiation therapy device.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of Center for Devices and Radiological Health (CDRH)
Michart. D. OHara
(Division Sign-Off) Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health .510(k) K132847
Page 1 of _ 1
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.